Identity
- Security key
- 14067
- Ticker
- DCTH
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2000-10-19
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- DCTH
Detail
Enriched 2026-08-14 20:47
- Market cap
- $593,696,382.45
- Shares outstanding (class)
- 34,698,795
- Shares outstanding (weighted)
- 34,698,795
- SIC
- 3841 SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Employees
- 156
- Location
- QUEENSBURY, NY
- Homepage
- https://www.delcath.com
- Description
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Market cap and share counts drift.